FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved a supplemental application for TRIUMEQ, a fixed-dose combination of abacavir, dolutegravir, and lamivudine, submitted by ViiV Healthcare Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Triumeq (dolutegravir/abacavir/lamivudine)

Snippet

SUPPL AP for TRIUMEQ (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE)